Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2287MR)

This product GTTS-WQ2287MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2287MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9586MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ3690MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ14943MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ15472MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ4601MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1761MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ14609MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ3150MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW